**Core Concept**
Platelet adhesion is a crucial process in the formation of thrombi, which can lead to a range of vascular disorders, including myocardial infarction and stroke. It involves the interaction of platelets with the vascular endothelium and the release of various adhesive proteins, such as von Willebrand factor and fibrinogen.

**Why the Correct Answer is Right**
The correct answer is a type of medication that inhibits platelet adhesion by blocking the action of various adhesion molecules. Specifically, it targets the glycoprotein IIb/IIIa receptor on platelets, which is essential for platelet aggregation and adhesion. By inhibiting this receptor, the medication prevents platelets from binding to von Willebrand factor and fibrinogen, thereby reducing the formation of thrombi.

**Why Each Wrong Option is Incorrect**
**Option A:** This medication is actually a stimulant of platelet adhesion, rather than an inhibitor. It works by releasing stored von Willebrand factor from platelet alpha-granules.
**Option B:** This medication has no effect on platelet adhesion. It is primarily used to inhibit platelet aggregation by blocking the action of cyclooxygenase.
**Option C:** This medication is a phosphodiesterase inhibitor that has vasodilatory effects, but it does not have a significant impact on platelet adhesion.

**Clinical Pearl / High-Yield Fact**
It's essential to remember that platelet inhibitors are crucial in the management of acute coronary syndromes and other thrombotic disorders. However, they can increase the risk of bleeding, particularly in patients with a history of gastrointestinal bleeding or those taking anticoagulant medications.

**Correct Answer:** D. Eptifibatide.